The AdaptDx Pro and Theia will change the future of AMD care because they make it easier for eye care professionals to test more patients and diagnose disease at an earlier stage.
Subclinical AMD Detection
Research reveals that impaired dark adaptation is the earliest biomarker of AMD. Diagnosis at the subclinical level is the best chance to preserve vision.
Breakthrough Technology Meets High-Touch Patient Care
Measuring dark adaptation speed with the AdaptDx Pro® can be useful in diagnosing AMD at the subclinical stage and managing this progressive disease with the hope of preventing unnecessary vision loss.
The AdaptDx Pro is amazing for two primary reasons. One, the portability of it is phenomenal. The other piece that’s critical is that Theia, the onboard AI tech, provides the instructions for the test, so patients get consistent instructions every time.
Latest News & Upcoming EventsView More
Dr. Francis Bynum and her team are focused on making early AMD detection the standard, not the exception. That begins by demonstrating the importance of dark adaptation testing and having educational conversations with their patients.
Once the test starts, Theia takes over to facilitate a consistent testing experience using automated instructions and adaptive feedback spoken directly to the patient in their native language.
It is not enough for doctors to believe in what new instrumentation can do for patients. To ensure your investments pay off, your staff must be willing to embrace them.